Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAVIG-1: New Adjuvant Vaccine in Glioblastoma
NCT06622434Phase 2Recruiting
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2024
- Primary completion
- Mar 2028
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of A52-Mel, A49-Mel and TERT/PTPRZ1 vaccine in glioblastoma (GBM), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoints: Maximum Tolerated Dose at 2 months and anti-TERT specific T cell responses at 2 months. Started Nov 2024; status: recruiting.
02
Drugs
A52-MelA49-MelTERT/PTPRZ1 vaccine
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT06622434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06622434.